Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

By C. Gisselbrecht, B. Glass, N. Mounier, Devinder Singh Gill, D. Linch, M. Trněný, A. Bosly, N. Ketterer, O. Shpilberg, H. Hagberg and 4 more. Journal of Clinical Oncology, 2010

1,516 citations recorded by the source corpus.

Subfields: Neurology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/62c6f71b23e4b5bebceba6846d3265cb2e97af64

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. G. Silva
2. M. Meignan
3. U. Vitolo
4. A. Jack
5. A. McMillan
6. A. López-Guillermo
7. A. Herrera
8. M. Ozcan

Citations in the corpus

• Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2019, background): “Platinum-based salvage therapy followed by high-dose chemotherapy and autologous stem-cell transplantation (ASCT) can cure 30%-40% of patients with relapsed/refractory (R/R) disease able to undergo this therapy.(7,8) However, prognosis is poor for most patients with R/R DLBCL who are ineligible for ”
• Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. (2021, neutral): “Decreased appetite 42 (25) 7 (4) 42 (25) 6 (4)”
• Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012, background): “In addition to initial prognostic factors, the nature of previous treatments and time from initial treatment are of utmost importance [63].”
• Discovery and Characterization of Super-Enhancer Associated Dependencies in Diffuse Large B-Cell Lymphoma (2013, neutral): “Mechanistic insights guiding the development of targeted therapeutic agents are urgently needed, as relapsed and refractory disease comprise significant unmet medical needs (Gisselbrecht et al., 2010).”
• Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. (2017, neutral): “Response rate, % (95% CI) 20 26 26 31 26 (21-31) CR rate 7 7 2 15 7 (3-15)”